Novartis, Roche, Genentech fined €444.85 million in France in AMD treatment case

The French competition authority, Autorité de la concurrence, has fined the pharmaceutical groups Novartis, Roche and Genentech, a combined €444.85 million for abuse of dominant position to impose the use of the drug Lucentis over its cheaper alternative Avastin in the treatment of age-related macular degeneration (AMD).

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Subscribe today

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation
  • Organisation-wide access across offices, people and devices

To continue reading this article register now.